A compound having one of the following structures (Vk), (Vl), (Vm), (Vn), (Vo) or (Vp): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein: R 1 is aryl or heteroaryl; R 30a and R 30b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 30a and R 30b join to form a carbocyclic or heterocyclic ring; or R 30a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 30b joins with R 31b to form a carbocyclic or heterocyclic ring; R 31a and R 31b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 31a and R 31b join to form a carbocyclic or heterocyclic ring; or R 31a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 31 joins with R 30b to form a carbocyclic or heterocyclic ring; R 32a and R 32b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 32a and R 32b join to form a carbocyclic or heterocyclic ring; or R 32a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 32b joins with R 33b to form a carbocyclic or heterocyclic ring; R 33a and R 33b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 33a and R 33b join to form a carbocyclic or heterocyclic ring; or R 33a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 33b joins with R 32b to form a carbocyclic or heterocyclic ring; L 1a is a bond, -NH-, alkylene, alkeneylene, heteroalkylene, heterocycloalkylene or heteroarylene; L 2 is a bond or alkylene; Q is -C(=O)-, -NR 34 C(=O)-, -S(=O) 2 - or - NR 34 S(=O) 2 -; R 34 is H, C 1 -C 6 alkyl or hydroxylalkyl; is a carbon-carbon double bond or a carbon-carbon triple bond; and R 35 and R 36 are each independently H, cyano, C 1 -C 6 alkyl, aminoalkyl, alkylaminoalkyl or hydroxylalkyl, or R 35 and R 36 join to form a carbocyclic or heterocyclic ring when is a double bond; or R 35 is absent and R 36 is H, C 1 -C 6 alkyl, aminoalkyl, alkylaminoalkyl or hydroxylalkyl when is a triple bond; wherein the prodrug is selected from acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group. R 1 is aryl or heteroaryl; R 30a and R 30b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 30a and R 30b join to form a carbocyclic or heterocyclic ring; or R 30a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 30b joins with R 31b to form a carbocyclic or heterocyclic ring; R 31a and R 31b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 31a and R 31b join to form a carbocyclic or heterocyclic ring; or R 31a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 31 joins with R 30b to form a carbocyclic or heterocyclic ring; R 32a and R 32b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 32a and R 32b join to form a carbocyclic or heterocyclic ring; or R 32a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 32b joins with R 33b to form a carbocyclic or heterocyclic ring; R 33a and R 33b are, at each occurrence, independently H, -OH, -NH 2, -CO 2 H, cyano, cyanoalkyl, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R 33a and R 33b join to form a carbocyclic or heterocyclic ring; or R 33a is H, -OH, -NH 2, -CO 2 H, cyano, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R 33b joins with R 32b to form a carbocyclic or heterocyclic ring; L 1a is a bond, -NH-, alkylene, alkeneylene, heteroalkylene, heterocycloalkylene or heteroarylene; L 2 is a bond or alkylene; Q is -C(=O)-, -NR 34 C(=O)-, -S(=O) 2 - or - NR 34 S(=O) 2 -; R 34 is H, C 1 -C 6 alkyl or hydroxylalkyl; is a carbon-carbon double bond or a carbon-carbon triple bond; and R 35 and R 36 are each independently H, cyano, C 1 -C 6 alkyl, aminoalkyl, alkylaminoalkyl or hydroxylalkyl, or R 35 and R 36 join to form a carbocyclic or heterocyclic ring when is a double bond; or R 35 is absent and R 36 is H, C 1 -C 6 alkyl, aminoalkyl, alkylaminoalkyl or hydroxylalkyl when is a triple bond; wherein the prodrug is selected from acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group.